Enliven Therapeutics (NASDAQ:ELVN) Issues Quarterly Earnings Results

Enliven Therapeutics (NASDAQ:ELVN) posted its earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06), FiscalAI reports.

Here are the key takeaways from Enliven Therapeutics’ conference call:

• Enliven is prioritizing a Phase 3 launch for ELVN‑001, expecting mid‑year regulator meetings to align on dose and design, an EHA data update in June, and to start the pivotal second‑line‑plus study before year‑end.
• Management highlighted strong Phase I results in a heavily pretreated population — reported MMRs in cohorts ~38–53% (cumulative 47–69%) with ~4.4% treatment discontinuation — and described the drug as highly tolerable with no new safety signals.
• Enliven positions ELVN‑001 to capture the post‑asciminib second‑line market (and potentially frontline later), arguing its ATP‑competitive mechanism avoids allosteric resistance and offers a cleaner long‑term safety/convenience profile versus some competitors.
• The company reports ~$460M in cash runway into H1 2029, which management says is sufficient to fund development through top‑line pivotal data for the planned second‑line ELVN‑001 trial.
• Enliven is seeking strategic partners for ELVN‑002 and has an undisclosed preclinical Graves’ disease program led by the founder, but offered no partner details or timelines and will prioritize ELVN‑001 development.

Enliven Therapeutics Stock Down 2.5%

Shares of ELVN opened at $28.75 on Wednesday. The stock has a market cap of $1.71 billion, a P/E ratio of -15.62 and a beta of 0.33. The business’s 50 day moving average price is $24.53 and its 200-day moving average price is $21.68. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.22.

Wall Street Analysts Forecast Growth

Several analysts have commented on ELVN shares. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Insider Buying and Selling at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.22, for a total value of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares of the company’s stock, valued at $20,828,417.36. The trade was a 10.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Heyman sold 9,635 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $25.03, for a total transaction of $241,164.05. Following the completion of the transaction, the director owned 25,545 shares in the company, valued at approximately $639,391.35. The trade was a 27.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 233,843 shares of company stock worth $6,145,489. 25.90% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Commodore Capital LP lifted its stake in shares of Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares in the last quarter. Vestal Point Capital LP raised its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after acquiring an additional 418,673 shares in the last quarter. Vanguard Group Inc. lifted its position in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after acquiring an additional 142,378 shares in the last quarter. Finally, State Street Corp boosted its stake in Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after purchasing an additional 87,725 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.